semorinemab (binds MAP-tau)
Jump to navigation
Jump to search
Indications
Adverse effects
- well tolerated[2]
- drug adverse effects of anti-Alzheimer monoclonal antibody
- drug adverse effects of pharmaceutical monoclonal antibodies
Mechanism of action
- binds N-terminal part of microtubule-associated protein tau (MAP-tau)
Clinical trials
- Lariat double-bind, placebo-controlled phase II trial reported reduced rate of cognitive decline with semorinemab at 49 weeks, but no benefit for functional decline[1]
- semorinemab does not slow clinical progression of Alzheimer's disease[2]
More general terms
Additional terms
References
- ↑ 1.0 1.1 AC Immune AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's Disease. https://ir.acimmune.com/news-releases/news-release-details/ac-immune-announces-first-positive-cognitive-results-tau
- ↑ 2.0 2.1 2.2 Teng E, Manser PT, Pickhorn K et al Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease. A Randomized Clinical Trial. JAMA Neurol. Published online June 13, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35696185 https://jamanetwork.com/journals/jamaneurology/fullarticle/2793069